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Inpatient Use of Computer-Guided Insulin Devices
Moving into the Non–Intensive Care Unit Setting
Roma Gianchandani, MD,1 and Guillermo E. Umpierrez, MD, CDE2
Basal-bolus insulin therapy is recommended as thepreferred regimen for management of hyperglycemia in
non–critically ill hospitalized patients with diabetes.1 Basal-
bolus insulin regimens with basal insulin analogs or
intermediate-acting insulin given once or twice a day, in com-
bination with short- or rapid-acting insulin administered prior to
meals, has been proven an effective and safe strategy for gly-
cemic management in non–critically ill patients.2,3 Additionally,
in non–cardiac general surgery patients, basal-bolus regimens
are also shown to reduce the risk of complications, especially
surgical-site infections.3 Unfortunately basal-bolus therapy is
associated with high rates of hypoglycemia, especially when
meal insulin and food intake do not match. In several observa-
tional and randomized control trials in non–intensive care unit
patients, the rate of hypoglycemia has ranged between 5% and
32%,2–4 which is a concern because hypoglycemia in non–
intensive care unit settings has been associated with increased
length of stay, hospital complications, and mortality.5,6
Despite well-outlined recommendations, basal-bolus ther-
apy is perceived to be complex and therefore inadequately
adopted for hyperglycemia management in all areas of the
hospital. Issues identified for underutilization include a fear of
hypoglycemia, which leads to insufficient starting doses of
insulin and inertia in routinely titrating them as is needed by the
changing requirements of a hospitalized patient.7 Many insulin
protocols have reported success in improving glucose man-
agement in the hospital including standardized basal-bolus
paper-based or electronic order sets, as well as education pro-
grams for providers, residents, and medical students,8–10 but
no simple fix has yet been identified.11 Some commercial
computer-guided insulin administration programs are now
available to guide basal-bolus insulin therapy in patients with
type 1 and type 2 diabetes (Glucommander [Glytec, Green-
ville, SC], EndoTool System [MD Scientific LLC, Charlotte,
NC], and GlucoStabilizer [Medical Decision Network,
Charlottesville, VA]). These devices may be especially useful
in hospitals with no diabetes management teams or diabetes
experts on staff; however, some are at a considerable financial
cost to the institution.
In this issue of the journal, Neubauer et al.12 present the
results of an open label uncontrolled intervention study
introducing a mobile device, the GlucoTab ( Joanneum Re-
search GmbH [Graz, Austria] and Medical University of Graz
[Graz]) system, which standardizes glycemic management
using a computerized decision support system for patients with
type 2 diabetes. This device provides dual functionality in-
cluding real-time guidance on insulin dosing for both provid-
ers and nurses. In addition, a screen interphase displays current
glucose values, glucose trends, and past administered insulin
doses, while allowing the capability to change insulin orders.
The GlucoTab system was evaluated in four wards in the
tertiary-care Graz hospital using varied hospital patients,
including cardiology, endocrinology, nephrology, and plastic
surgery. Patients differed significantly in their levels of in-
sulin resistance, and the providers differed in their knowl-
edge of basal-bolus insulin therapy. Providers were educated
in the basics of insulin treatment and the device prior to the
study start. Standard published basal-bolus algorithms from
previous randomized controlled prospective trials were used
in the GlucoTab system, with total daily starting insulin doses
of 0.3 or 0.5 units/kg/day, depending on the renal function of
patients.2,3,13 Normal basal bolus ratios are approximately
50% basal and 50% bolus, with bolus doses further divided
somewhat equally among three meals. In this study (device)
Neubauer et al.12 evaluated a modified bolus dose algorithm
that split the bolus dose into 45% of bolus dose at breakfast,
25% at lunch, and 30% at dinner. This modification from the
standard protocols came about after the observation of higher
caloric intake or higher postprandial glucose excursion after
breakfast compared with other meals during the day.
This higher requirement may be due to a combination of
factors, including a large carbohydrate load at breakfast
frequently provided in hospitals, the dawn phenomenon, or
a late breakfast with delayed insulin administration. The
GlucoTab system algorithm using the variable bolus dose
worked well and allowed over 50% of their patients to
reach a glucose goal of 70–140 mg/dL, with low levels of
hypoglycemia.
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Percentages of patients in the study of Neubauer et al.12
reaching glucose goals varied among the different ward
specialties, with cardiology and nephrology being the lowest.
Acute cardiology patients had higher glucose levels and
probably represent the most insulin resistant of the study
group. In contrast, the nephrology group was treated as the
most insulin sensitive and initiated with a lower starting dose
of insulin at 0.3 units/kg/day, and fewer patients reached goal
glucose levels. Because patients were varied in renal func-
tion, reason for admission, and nutritional support, the
GlucoTab algorithm may perform better with several different
starting insulin doses, but unfortunately this may complicate
use of the device by nondiabetes experts. Regression analysis
performed to analyze this diverse patient population identified
four predictors of poor glycemic outcome: insulin treatment
prior to admission, higher pre-admission glycated hemoglobin
levels, higher starting insulin doses in the hospital, and acuity
of admissions.
Even with these few limitations, it is encouraging that the
GlucoTab system in the hands of nondiabetes experts allowed
the target mean blood glucose of 70–140 mg/dL (mean
achieved value, 154– 35 mg/dL) to be reached in a large
percentage of patients compared with prior clinical trials of
basal-bolus therapy performed by expert trained providers
(66% in RABBIT 22 and 52% in RABBIT 2 Surgery3). This
was accomplished with a similar or slightly lower risk of
hypoglycemia and no episodes of severe hypoglycemia
compared with RABBIT 2 Surgery.3
Many factors may have contributed to the low hypogly-
cemia rates. The insulin on-board calculator, a safety feature
in insulin pumps, seems to perform an important function for
the GlucoTab system. It tracks insulin doses, calculates the
active insulin remaining from the patient’s last injection, and
provides guidance on reducing insulin doses at administra-
tion time. This adjustment is not intuitively made when a
provider orders or a nurse administers insulin and is of par-
ticular importance in hospitals with meal service, where food
and insulin are not given in the traditional 4–6-h intervals.
Another important aspect of hypoglycemia prevention may
have been the timing of administration of long-acting insulin
(glargine). The study dosed glargine in the afternoon after
rounds, allowing providers to evaluate the 24-h response to
the last insulin dose before modifying it and also reducing the
dose if the injection was delayed. In our experience hospi-
talized patients, especially those with renal failure, are very
insulin sensitive overnight and have less hypoglycemia with
daytime basal insulin administration.
Computer-guided devices are an evolving and welcome
technology in the diabetes field and may facilitate glucose
control and reduce hypoglycemia, especially when no
diabetes teams or experts are available to direct insulin
therapy. This trial introduces an efficacious device, which
potentially can simplify glucose management in hospital-
ized patients. The GlucoTab system has a fine-tuned algo-
rithm and design interphase that was well accepted by staff
and allowed a significant number of patients to reach goal
even in the hands of teams not expert in basal-bolus insulin
therapy. As a clinical tool this device would be significantly
more powerful if it could be integrated into an electronic
medical record system as a basal bolus calculator for or-
dering insulin.
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